Vimarsana
Biggest News Aggregation in the World

Page 13 - Structural Heart News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Structural Heart. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Structural Heart Today - Breaking & Trending Today

Abbott and Damar Hamlin Team up to Build Heart Health Community With New HeartMates Program - Vimarsana News

Abbott and Damar Hamlin Team up to Build Heart Health Community With New HeartMates Program

Abbott (NYSE: ABT), a global leader in heart health, announced today the Abbott HeartMates program, a new initiative that will kick off with professional football player Damar Hamlin as its first ambassador. Experiencing a major heart-related incident can cause emotional distress and be an incredibly isolating ...

Abbott and Damar Hamlin Team Up To Build Heart Health Community With ... - Vimarsana News

Abbott and Damar Hamlin Team Up To Build Heart Health Community With ...

Abbott and Damar Hamlin Team Up To Build Heart Health Community With ...

Abbott teams up with Damar Hamlin for 'HeartMates Program' - Vimarsana News

Abbott teams up with Damar Hamlin for 'HeartMates Program'

Abbott (NYSE: ABT) today announced a new initiative around its HeartMate system with Buffalo Bills safety Damar Hamlin.

Medtronic Evolut TAVR Platform Outperforms Surgery with Sustained Valve Performance for Low-risk Patients at Four Years - Vimarsana News

Medtronic Evolut TAVR Platform Outperforms Surgery with Sustained Valve Performance for Low-risk Patients at Four Years

TCT 2023: Medtronic adds to the body of evidence for Evolut TAVR with late-breaking clinical trial data from the Evolut Low Risk Trial

TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION - Vimarsana News

TRISCEND II SIX-MONTH DATA FOR FIRST 150 PATIENTS SUCCESSFULLY DEMONSTRATE SAFETY AND EFFICACY OF EDWARDS EVOQUE SYSTEM FOR SEVERE TRICUSPID REGURGITATION

/PRNewswire/ -- Edwards Lifesciences Corporation (NYSE: EW) today announced successful results from TRISCEND II, a randomized controlled pivotal trial designed...